期刊
LANCET ONCOLOGY
卷 20, 期 8, 页码 E452-E463出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(19)30171-8
关键词
-
类别
资金
- Agence National de la Recherche (ANR)
- Association pour la Recherche sur le Cancer (ARC)
- Institut National du Cancer (INCa) [INCa-DGOS-Inserm_12551]
- Fondation pour la Recherche Medicale (FRM)
- Breakthrough Level 2 grant from the US Department of Defense Breast Cancer Research Program [BC180476P1]
- Department of Radiation Oncology at Weill Cornell Medicine
- Lytix
- Phosplatin
- Ligue contre le Cancer (equipe labellisee)
- ANR-Projets Blancs
- ANR
- ARC
- Canceropole Ile-de-France
- Chancelerie des universites de Paris (Legs Poix)
- FRM
- European Commission (ArtForce)
- European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR)
- European Research Council
- Fondation Carrefour
- INCa
- Inserm Heterogeneity of Tumors and Ecosystem Progam
- Institut Universitaire de France
- LeDucq Foundation
- LabEx Immuno-Oncology
- Recherche Hospitalo-Universitaire Torino Lumiere
- Seerave Foundation
- Sistema Integrado do Registro e Identificacao Civil (SIRIC) Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
- SIRIC Cancer Research and Personalized Medicine (CARPEM)
Immunotherapy is radically changing the clinical management of patients affected by an increasingly wide array of tumours. However, not all patients achieve long-term clinical benefits from immunotherapy as a standalone treatment, calling for the development of regimens that combine various interventions. Radiotherapy stands out as a particularly promising candidate in this setting, not only because of its established safety profile, but also because radiotherapy has the potential ability to mediate robust immunostimulatory effects that could synergise with immunotherapy in systemic tumour control. However, optimal radioimmunotherapy regimens might call for the redefinition of conventional radiotherapy doses and fractionation schedules. In this Series paper, we discuss current approaches to improve the efficacy and reduce the toxicity of radioimmunotherapy for the management of cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据